About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

05 Insightful Analyst Questions From Amphastar Pharmaceuticals’s Q2 Earnings Call

By: StockStory

AMPH Cover Image

Amphastar Pharmaceuticals delivered a mixed second quarter, with management highlighting BAQSIMI’s strong sales momentum as a key driver amid ongoing pressures in legacy products. While the company’s non-GAAP profitability was above expectations, management pointed to increased competition in glucagon and epinephrine lines as factors behind revenue softness and margin compression. CFO William J. Peters explained, “We’re proud to share that while revenue was impacted by increased competition in our legacy products, this was largely offset by BAQSIMI, which recorded its highest quarterly sales since the product’s acquisition.”

Is now the time to buy AMPH? Find out in our full research report (it’s free).

Amphastar Pharmaceuticals (AMPH) Q2 CY2025 Highlights:

  • Revenue: $174.4 million vs analyst estimates of $176.1 million (4.4% year-on-year decline, 1% miss)
  • Adjusted EPS: $0.85 vs analyst estimates of $0.74 (14.6% beat)
  • Adjusted EBITDA: $63.18 million vs analyst estimates of $53.54 million (36.2% margin, 18% beat)
  • Operating Margin: 24.2%, down from 30.3% in the same quarter last year
  • Market Capitalization: $1.42 billion

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Amphastar Pharmaceuticals’s Q2 Earnings Call

  • Serge D. Belanger (Needham & Company) asked if Amphastar’s flat revenue outlook had changed and about BAQSIMI’s trajectory. CFO William J. Peters reaffirmed flat sales guidance and said BAQSIMI’s growth is tracking with earlier forecasts, supported by the MannKind partnership.
  • Yijun Chen (Wells Fargo) questioned the long-term opportunity for the GLP-1 generic (AMP-018) given market contraction. Peters replied that the GLP-1 market is expected to be crowded, limiting its near-term revenue impact.
  • Pavan R. Patel (Bank of America) inquired about margin trends and epinephrine competition. Peters indicated margins will face pressure from price competition, but new products should help stabilize the margin profile if approved.
  • Ekaterina V. Knyazkova (JPMorgan) asked about further glucagon erosion and the rationale for U.S. manufacturing expansion. Peters expects ongoing glucagon declines and explained the expansion is aimed at supporting the proprietary pipeline and mitigating geopolitical risks.
  • David A. Amsellem (Piper Sandler) probed on whether 2025 revenue targets assumed AMP-002 approval and which launches were included. Peters said guidance risk-adjusts for two launches (AMP-002 and AMP-015), but BAQSIMI outperformance could also help meet the target.

Catalysts in Upcoming Quarters

In upcoming quarters, our analysts will focus on (1) progress toward FDA approval and commercial launch of AMP-002 and AMP-015, (2) the pace and impact of Amphastar’s U.S. manufacturing expansion on pipeline execution, and (3) the ability to sustain BAQSIMI’s growth amid increasing competition in glucagon and epinephrine markets. Cost containment and margin stabilization efforts will also be important markers of performance.

Amphastar Pharmaceuticals currently trades at $30.31, up from $21.65 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

High-Quality Stocks for All Market Conditions

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

More News

View More
Microsoft Stock Hits Stride in 2025—How Much More Can It Run?
Via MarketBeat
Topics Artificial Intelligence Retirement
Tickers MSFT
How Berkshire's OxyChem Buy Cements Its Long-Term Strength
Via MarketBeat
Tickers BRK BRK-A BRK-B OXY
Oklo Insiders Sell! Oh No! This Is Why Investors Shouldn’t Worry
Via MarketBeat
Tickers OKLO
Rocket Lab's Electron: The Quiet Workhorse Powering Momentum
Via MarketBeat
Tickers RKLB
Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore
Via MarketBeat
Topics Artificial Intelligence
Tickers NOW
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.